Table 3.
Univariate Cox regression model results for patients surviving >3 months after SBRT.
| Hazard ratio | Lower CL | Upper CL | Prob ChiSq | |
|---|---|---|---|---|
| ADT + docetaxel received | 11.508 | 0.501 | 264.091 | 0.1265 |
| ADT refractory, no docetaxel | 3.239 | 0.119 | 88.286 | 0.4859 |
| PSA increased | 1.982 | 0.191 | 20.608 | 0.567 |
| Previous RT in SBRT field | 3.308 | 0.826 | 13.245 | 0.0909 |
| Age <65 years | 2.254 | 0.596 | 8.528 | 0.2312 |
| CTV >22 | 3.15 | 0.69 | 14.374 | 0.1384 |
| Gleason score >7 | 1.341 | 0.261 | 6.897 | 0.7257 |
| ADT untreated | 6.467 | 0.318 | 131.363 | 0.2243 |
| Non-lymph node site | 5.975 | 0.925 | 38.582 | 0.0603 |
| Polymetastatic disease | 6.519 | 1.016 | 41.816 | 0.048 |
| Docetaxel received | 4.338 | 0.889 | 21.164 | 0.0696 |